FranceFrance

The stock market celebrates Genfit's Phase II results

06.02.2012

Shares of the French diabetes specialist almost doubled when the company
published results of its Phase II study with the PPAR alpha and delta
modulator GFT505. The compound has met the co-primary and secondary
endpoints while showing no adverse side-effects. It helped to improve
insulin sensitivity in the liver and peripheral tissues. It is intended to
treat non-alcoholic fatty liver disease (NAFLD)/non-alcoholic
steatohepatitis (NASH). The product significantly reduced insulin-induced
hepatic glucose production by 0.86 mg/kg/min from baseline to week 8 vs.
0.63 mg/kg/min for placebo (p=0.006). The single blinded trial in French
centres enrolled 22 insulin-resistant patients with abdominal obesity.

GFT505 is the most advanced compound of a group of drug candidates developed by Genfit. It targets multiple risk factors of pre-diabetes and diabetes: hyperglycaemia and insulin resistance, atherogenic dyslipidemia and
inflammation, as well as certain liver disorders often associated with
pre-diabetic and diabetic states. Genfit was founded in 1999 Loos/France.
The company employs about 100 people and is listed at Alternext on the NYSE
Euronext Stock Exchange. The biotech still owns global rights to all of its
compounds.

FranceFrance

19.08.2011

Marcy l’Etoile – French in vitro diagnostics group Biomérieux S.A. informed the markets that it has acquired Argene, a French company specialising in molecular diagnostics for immuno­compromised patients. Biomérieux said it was...

FranceFrance

17.08.2011

Paris – A team consisting of French scientists and biotech start-up Epixis SA has developed a novel hepatitis C vaccine based on retrovirus-derived virus-like particles (VLPs) pseudotyped with the heterologous viral envelope...

FranceFrance

10.08.2011

Neuilly/New York - Les Laboratoires Servier and Intercept Pharmaceuticals join forces for the development of diabetes drugs. France’s largest independent pharmaceutical company and the US biotech entered into a worldwide ex-U.S....

FranceFrance

20.07.2011

Paris/New Haven - Sanofi pays a $9m milestone payment to Rib-X Pharmaceuticals, Inc. The French pharmaceutical company recently signed worldwide research collaboration and option for license for novel classes of antibiotics...

FranceFrance

12.07.2011

French drug maker Sanofi SA announced mixed results of a late-stage trial of multiple sclerosis drug Lemtrada. The two-year study CARE-MS I is the first of two randomised, Phase 3 clinical trials comparing Sanofi's alemtuzumab to...

FranceFrance

05.07.2011

French Biotech BioAlliance Pharma S.A. has announced plans to raise up toEUR 16.6 million through the sale 3.4 million shares at EUR 4.90 in a rightsissue. The price is a 20% discount to BioAlliance's closing price of EUR6.10...

FranceFrance

14.06.2011

Paris – Pulmonary arterial hypertension (PAH), a severe disease of the arterial blood vessels in the lungs, leads to chronically elevated pulmonary artery pressure and remodelling of the small pulmonary arteries (SMPs) as a...

FranceFrance

11.06.2011

Montpellier – French researchers have identified the factor that renders human dendritic and myeloid cells largely refractory to HIV-1 infection. Overexpression of the SAMHD1 protein in cell culture effectively blocked infection...

Displaying results 21 to 30 out of 268

< Previous 21-30 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-france/browse/2/article/the-stock-market-celebrates-genfits-phase-ii-results-1.html

Product of the week

Products

Events

All Events

Current issue

All issues